Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy

Oncologist

Volumn 10, Issue 6, 2005, Pages 370-381

  Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Breast cancer; Dose dense; Geometry; Gompertzian; Growth kinetics; Mathematics; Mitosis; Self metastasis; Self seeding

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN CITRATE; TRASTUZUMAB;

APOPTOSIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL DENSITY; CELL KILLING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; FIBROBLAST; HUMAN; METASTASIS; MICROENVIRONMENT; MITOSIS; MODEL; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PORTRAITS; STEM CELLS; TUMOR STEM CELLS;

EID: 22244440256     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-6-370     Document Type: Conference Paper

References (46)

1. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:1557-1602.
2. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-lll.
3. Van der Auwera I, Van Laere SJ, Van den Eynden GG et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004;10:7965-7971.
4. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. The Oncologist 2004;9(suppl 5):18-30.
5. Guidi AJ, Berry DA, Broadwater G et al. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol 2002;20:732-742.
6. Munster PN, Norton L. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res 2001;3:361-364.
7. Norton L. Adjuvant breast cancer therapy: current status and future strategies-growth kinetics and the improved drug therapy of breast cancer. Semin Oncol 1999;26(suppl 3):1-4.
8. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-7071.
9. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(suppl 10):S10-3-S10-10.
10. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. The Oncologist 2001;6(suppl 3):30-35.
11. Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol 2003;21:1425-1428.
12. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
13. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479-1499.
14. Skipper HE. Analysis of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities. Southern Research Institute Booklet 7, 1986;420:87-92.
15. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995;273:542-547.
16. Bonadonna G, Zambetti M, Moliterni A et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004;22:1614-1620.
17. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
18. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial c9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431-1439.
19. Hudis C, Seidman A, Baselga J et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93-100.
20. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
21. Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999;26(suppl 2):11-20.
22. Former MN, Seidman AD, Schwartz MK et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16:234-239.
23. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98a.
24. Norton L, Slamon D, Leyland-Jones B et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999;18:127a.
25. Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-2068.
26. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
27. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002;20:743-750.
28. Norton L. High-dose chemotherapy for breast cancer: "how do you know?" J Clin Oncol 2001;19:2769-2770.
29. Dey P, Mohanty SK. Fractal dimensions of breast lesions on cytology smears. Diagn Cytopathol 2003;29:85-86.
30. Baish JW, Jain RK. Fractals and cancer. Cancer Res 2000;60:3683-3688.
31. Cross SS. Fractals in pathology. J Pathol 1997;182:l-8.
32. Ohri S, Dey P, Nijhawan R. Fractal dimension in aspiration cytology smears of breast and cervical lesions. Anal Quant Cytol Histol 2004;26:109-112.
33. Einstein AJ, Wu HS, Sanchez M et al. Fractal characterization of chromatin appearance for diagnosis in breast cytology. J Pathol 1998;185:366-381.
34. Velanovich V. Fractal analysis of mammographic lesions: a prospective, blinded trial. Breast Cancer Res Treat 1998;49:245-249.
35. Pierce DF Jr, Gorska AE, Chytil A et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 1995;92:4254-4258.
36. Tamaru N, Hishikawa Y, Ejima K et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004;84:1460-1471.
37. Sirvent JJ, Aguilar MC, Olona M et al. Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. Histol Histopathol 2004;19:759-770.
38. Hasebe T, Sasaki S, Imoto S et al. Prognostic significance of the intra-vessel tumor characteristics of invasive ductal carcinoma of the breast: a prospective study. Virchows Arch 2004;444:20-27.
39. Archer CD, Parton M, Smith IE et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003;89:1035-1041.
40. Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome in breast cancer. Nature 2002;415:530-536.
41. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549.
42. Kuperwasser C, Chavarria T, Wu M et al. Reconstitution of functionally normal and malignant human breast tissue in mice. Proc Natl Acad Sci USA 2004;101:4566-4571.
43. Ronnov-Jessen L, Petersen OW, Koteliansky VE et al. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995;95:859-873.
44. Gudjonsson T, Ronnov-Jessen L, Villadsen R et al. To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia. Methods 2003;30:247-255.
45. Rizki A, Bissell MJ. Homeostasis in the breast: it takes a village. Cancer Cell 2004;6:1-2.
46. Radisky DC, Bissell MJ. Cancer. Respect thy neighbor! Science 2004;303:775-777.